Searched for
SPARC SUN PHARMA
Sun Pharma inks licensing pact with SPARC to commercialise medication in US marketSPARC submitted a new drug application (NDA) to the US Food and Drug Administration (US FDA) for the said product in February 2022.- SPARC Q1 net loss widens to Rs 78.84 croreSPARC was formed in 2007, when Sun Pharmaceutical Industries separated out its active projects in drug discovery and innovation into a new ...
- SPARC, Sun Pharma climb on licensing agreementThe deal will make the company eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPS...
- SPARC and Sun Pharma ink licensing pact for epilepsy drug"As per the agreement, SPARC will license Elepsia XRTM (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma ...
- Expect delay in start of royalty from 2 new drugs: SPARCSun Pharma Advanced Research Company (SPARC) expects further delay in start of royalty income from its two new drug applications, including...
- Sparc, Sun Pharma move up in lockstep on D-StreetSun Pharma Advanced Research Co (Sparc), the drug discovery business owned by the promoter group of Sun Pharma, is fast emerging.
- SPARC, Sun Pharma drop on USFDA revocation of approvalShares of SPARC closed 2.62 per cent lower at Rs 375.80 after hitting the day's low of Rs 368.50 on the exchange. Parent Sum Pharma ended 3...
- Sun Pharma Advanced Research Company reports net loss of Rs 1.65 crore in Q1Sun Pharma Advanced Research Company (SPARC) today reported a net loss of Rs 1.65 crore for the first quarter ended June 30, 2015-16.
- SPARC licenses Xelpros to Sun Pharma for US marketSun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the ...
- SPARC to raise Rs 250 crore through rights issueSun Pharma Advanced Research Company was demerged from Sun Pharma as a pharma research and drug discovery company in 2007.
- SPARC net loss widens to Rs 9.40 crore in Q4Sun Pharma Advanced Research Company (SPARC) today reported a net loss of Rs 9.40 crore for the fourth quarter ended March 31, 2015.
- Pharma space still attractive: Mayuresh Joshi'In the pharma industry, the generic space is looking extremely attractive to us and within the generic space, we are really liking Sun Pha...
- USFDA disapproves Sun Pharma unit's product in present formSun Pharma Advanced Research Company said the US health regulator has disapproved its New Drug Application for an anti-depressant product i...
- SPARC Q2 net loss at Rs 7.65 croreSun Pharma Advanced Research Company reported a net loss of Rs 7.65 crore for the second quarter ended September 30, 2013.
- Sun Pharma Advanced Research Company (SPARC) Q2 net loss at Rs 24 croreSun Pharma Advanced Research Company (SPARC) today posted a net loss of Rs 24.12 crore for the second quarter ended September 30.
- Drug discovery firm SPARC Q1 loss widens to Rs 18 croreThe company had posted a net loss of Rs 11.26 crore for the same period of 2011-12 fiscal, SPARC said in a statement.
- Sun Pharma Advanced Research Company's Q4 net loss at Rs 21.58 croreSun Pharma Advanced Research Company today posted a loss of Rs 21.58 crore for the quarter ended March 31, 2012.
- SPARC reports Q1 net loss at Rs 11.26 croreSun Pharma Advanced Research Company (SPARC) today posted a net loss of Rs 11.26 crore for the first quarter ended June 30, 2011.
- Merck, Sun Pharma ink JV to bring innovative drugs to EMsSun Pharmaceutical will bring its product development skills to the table, while Merck will help with market presence.
- HC approves Sun Pharma demergerSun Pharmaceuticals announced on Thursday that the Gujarat High Court had approved the company’s demerger of its ‘innovative’ research and ...
Load More
